Redeye provides a brief comment on Scibase receiving an initial order valued at approximately SEK8m ...
Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue ...
Redeye believes the data is solid and in line with previous readouts.
Bioteknikbolaget Aptahem, som utvecklar läkemedelskandidaten Apta-1 mot sepsis, har tagit ett strate...
Redeye comments on the directed share issue in which Sivers Semiconductors raised SEK95m before tran...
Atria announced today its TOGETHER 2030 strategy for 2025-30 with refined financial targets.
We initiate coverage of YIT with a REDUCE-rating and TP of EUR 3.
Redeye is positive on Senzime’s recent news flow, with contracts from important US hospitals.
Redeye comments on Verve's announced acquisition. The company is acquiring Acardo Group for EUR24.
Redeye leaves a comment following OncoZenge’s announcement of a collaboration with UCLA, marking an ...
Redeye comments on the announcement that CEO Pål Ryfors will step down of his own volition, with cur...
Redeye is pleased with TO13’s preliminary subscription rate of 91%.
Grangex nya DFS för Sydvaranger ökar visibiliteten och pekar på ytterligare värden.
Redeye returns with minor estimate changes following a mixed report from Binero that faced higher OP...
Redeye comments on Cinclus’ announcement that the first patient has been screened in its pivotal Pha...
